Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation
Open Access
- 1 June 2019
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 212, 113-119
- https://doi.org/10.1016/j.ahj.2019.02.001
Abstract
No abstract availableFunding Information
- Janssen Scientific Affairs
This publication has 24 references indexed in Scilit:
- Coding of obesity in administrative hospital discharge abstract data: accuracy and impact for future research studiesBMC Health Services Research, 2014
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationThe New England Journal of Medicine, 2011
- An automated database case definition for serious bleeding related to oral anticoagulant usePharmacoepidemiology and Drug Safety, 2011
- Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 CountriesAmerican Journal of Epidemiology, 2011
- A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial FibrillationSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2010
- Low Diagnostic Yield of Elective Coronary AngiographyThe New England Journal of Medicine, 2010
- Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based ApproachSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2010
- Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy SubjectsThe Journal of Clinical Pharmacology, 2007
- Obesity and the Risk of New-Onset Atrial FibrillationJAMA, 2004
- Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial FibrillationThe New England Journal of Medicine, 1992